Compare XAIR & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | BRTX |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.1M |
| IPO Year | 2015 | 2015 |
| Metric | XAIR | BRTX |
|---|---|---|
| Price | $2.59 | $2.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $20.00 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 60.4K | 25.1K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | $81,000.00 |
| Revenue This Year | $4.23 | $290.60 |
| Revenue Next Year | $108.84 | $64.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $0.14 |
| 52 Week High | $8.19 | $4.10 |
| Indicator | XAIR | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 54.32 |
| Support Level | $2.38 | $0.22 |
| Resistance Level | $2.66 | $2.93 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 27.73 | 26.15 |
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.